NEUTRALIZING ANTIBODY-RESPONSE DURING HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION - TYPE AND GROUP SPECIFICITY AND VIRAL ESCAPE

被引:69
|
作者
ARENDRUP, M
SONNERBORG, A
SVENNERHOLM, B
AKERBLOM, L
NIELSEN, C
CLAUSEN, H
OLOFSSON, S
NIELSEN, JO
HANSEN, JES
机构
[1] CENT MICROBIOL LAB, STOCKHOLM, SWEDEN
[2] NATL VET INST, CTR BIOMED, DEPT VIROL, UPPSALA, SWEDEN
[3] ROYAL DENT COLL, PANUM INST, DEPT ORAL DIAGNOST, DK-2100 COPENHAGEN, DENMARK
[4] GOTHENBURG UNIV, DEPT CLIN VIROL, S-41124 GOTHENBURG, SWEDEN
[5] STATENS SERUM INST, DEPT VIROL, DK-2300 COPENHAGEN, DENMARK
来源
关键词
D O I
10.1099/0022-1317-74-5-855
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The paradox that group-specific neutralizing antibodies (NA) exist in the majority of human immunodeficiency virus type 1 (HIV-1)-infected patients, whereas the NA response against autologous HIV-1 virus isolates is highly type-specific, motivated us to study the type- and group-specific NA responses generated upon presentation of escape virus, and the viral epitopes involved in the escape. Patients with demonstrable escape virus all developed group-specific NA, which were detectable after a delay and disappeared prior to disease development. The sera tested inhibited the binding of recombinant soluble gp120IIIB to cell-associated CD4, but group-specific virus neutralization required binding of NA to HIV-I prior to viral attachment to target cells. Consecutive escape virus isolates were tested for sensitivity to neutralization by heterologous sera. Only minor differences were demonstrated, suggesting that the majority of the change in neutralization sensitivity is driven by the selective pressure of type-specific NA. Furthermore, no differences were observed in sensitivity to neutralization by anti-carbohydrate neutralizing monoclonal antibodies or the lectin concanavalin A, indicating a conserved nature of certain carbohydrate neutralization epitopes during escape. Finally the V3 sequence of three sets of consecutive virus isolates were analysed revealing amino acid mutations in V3 sequences of all escape virus isolates. The biological significance of these variations was confirmed further by the demonstration of changes in sensitivity to neutralization by anti-V3 monoclonal antibodies. These results strongly suggest a participation of the NA response against the V3 loop in the immunoselection of escape virus.
引用
收藏
页码:855 / 863
页数:9
相关论文
共 50 条
  • [31] LABORATORY TESTS FOR DETECTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    NUWAYHID, NF
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1995, 2 (06) : 637 - 645
  • [32] PSYCHONEUROIMMUNOLOGY AND HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION REVISITED - REPLY
    PERRY, S
    RABKIN, J
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 1994, 51 (03) : 247 - 248
  • [33] INFECTION OF MACACA-NEMESTRINA BY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    AGY, MB
    FRUMKIN, LR
    COREY, L
    COOMBS, RW
    WOLINSKY, SM
    KOEHLER, J
    MORTON, WR
    KATZE, MG
    [J]. SCIENCE, 1992, 257 (5066) : 103 - 106
  • [34] TREATMENT TRIALS FOR PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    NIU, MT
    STEIN, DS
    SCHNITTMAN, SM
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (06): : 1601 - 1602
  • [35] INHIBITION OF INFECTION WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 BY SULFATED GANGLIOSIDES
    HANDA, A
    HOSHINO, H
    NAKAJIMA, K
    ADACHI, M
    IKEDA, K
    ACHIWA, K
    ITOH, T
    SUZUKI, Y
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 175 (01) : 1 - 9
  • [36] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION IN A COMMUNITY OF SOUTHERN MOZAMBIQUE
    MENCARINI, P
    DELUCA, A
    GHIRGA, P
    VICHI, F
    ANTINORI, A
    MAIURO, G
    NOORMAHOMED, I
    TAMBURRINI, E
    [J]. TROPICAL AND GEOGRAPHICAL MEDICINE, 1991, 43 (1-2): : 39 - 41
  • [37] INFECTION OF ACCESSORY DENDRITIC CELLS BY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    LANGHOFF, E
    HASELTINE, WA
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1992, 99 (05) : S89 - S94
  • [38] IGA NEPHROPATHY IN A CHILD WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    TRACHTMAN, H
    GAUTHIER, B
    VINOGRAD, A
    VALDERRAMA, E
    [J]. PEDIATRIC NEPHROLOGY, 1991, 5 (06) : 724 - 726
  • [39] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 CANDIDATE VACCINE BREAKTHROUGH INFECTION
    MASCOLA, JR
    MCNEIL, JG
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (06): : 1636 - 1637
  • [40] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION AND BREAST-MILK
    DEMARTINO, M
    TOVO, PA
    GALLI, L
    GABIANO, C
    [J]. ACTA PAEDIATRICA, 1994, 83 : 51 - 58